CREDIT SUISSE First Boston has won the mandate for a sale of shares in a privately owned Russian company, a rarity in the international markets but also a transaction that investors are expected to greet enthusiastically. The shares in Akrikhin, a pharmaceutical concern, will offer international institutions a welcome alternative to companies that still have strong links to the government. Investors are seeking shares in private companies as they offer a purer play on economic recovery, while many such companies are chronically undervalued.
April 24, 1998